Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor

Journal of Immunology

Volumn 190, Issue 6, 2013, Pages 2984-2993

  Yaddanapudi, Kavitha ^a   Putty, Kalyani ^a   Rendon, Beatriz E ^a   Lamont, Gwyneth J ^a   Faughn, Jonathan D ^a   Satoskar, Abhay ^b   Lasnik, Amanda ^c   Eaton, John W ^a   Mitchell, Robert A ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 6 PHENYLPYRIMIDINE; ANTINEOPLASTIC AGENT; MACROPHAGE MIGRATION INHIBITION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MACROPHAGE ACTIVATION; MALE; MELANOMA; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR PROMOTION; TUMOR VASCULARIZATION; WILD TYPE;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELLS, CULTURED; LUNG NEOPLASMS; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES, PERITONEAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC;

EID: 84874877157     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201650     Document Type: Article

References (63)

1. Wolchok, J. D., and Y. Saenger. 2008. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13(Suppl. 4): 2-9.
2. Dranoff, G. 2009. Targets of protective tumor immunity. Ann. N. Y. Acad. Sci. 1174: 74-80.
3. Hoos, A., R. Ibrahim, A. Korman, K. Abdallah, D. Berman, V. Shahabi, K. Chin, R. Canetta, and R. Humphrey. 2010. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37: 533-546.
4. Korn, E. L., P. Y. Liu, S. J. Lee, J. A. Chapman, D. Niedzwiecki, V. J. Suman, J. Moon, V. K. Sondak, M. B. Atkins, E. A. Eisenhauer, et al. 2008. Metaanalysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26: 527-534.
5. Mantovani, A., and A. Sica. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22: 231-237.
6. Melief, C. J. 2008. Cancer immunotherapy by dendritic cells. Immunity 29: 372- 383.
7. Loke, P., and J. P. Allison. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100: 5336-5341.
8. Huber, S., R. Hoffmann, F. Muskens, and D. Voehringer. 2010. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood 116: 3311-3320.
9. Terrazas, L. I., D. Montero, C. A. Terrazas, J. L. Reyes, and M. Rodríguez-Sosa. 2005. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis. Int. J. Parasitol. 35: 1349-1358.
10. Crowther, M., N. J. Brown, E. T. Bishop, and C. E. Lewis. 2001. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J. Leukoc. Biol. 70: 478-490.
11. Luo, Y., H. Zhou, J. Krueger, C. Kaplan, S. H. Lee, C. Dolman, D. Markowitz, W. Wu, C. Liu, R. A. Reisfeld, and R. Xiang. 2006. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116: 2132- 2141.
12. Bernhagen, J., T. Calandra, R. A. Mitchell, S. B. Martin, K. J. Tracey,W. Voelter, K. R. Manogue, A. Cerami, and R. Bucala. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759.
13. Calandra, T., L. A. Spiegel, C. N. Metz, and R. Bucala. 1998. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc. Natl. Acad. Sci. USA 95: 11383- 11388.
14. McDevitt, M. A., J. Xie, G. Shanmugasundaram, J. Griffith, A. Liu, C. McDonald, P. Thuma, V. R. Gordeuk, C. N. Metz, R. Mitchell, et al. 2006. A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. J. Exp. Med. 203: 1185-1196.
15. Abe, R., T. Peng, J. Sailors, R. Bucala, and C. N. Metz. 2001. Regulation of the CTL response by macrophage migration inhibitory factor. J. Immunol. 166: 747- 753.
16. Zhou, Q., X. Yan, J. Gershan, R. J. Orentas, and B. D. Johnson. 2008. Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J. Immunol. 181: 1877-1886.
17. Krockenberger, M., Y. Dombrowski, C. Weidler, M. Ossadnik, A. Hönig, S. Häusler, H. Voigt, J. C. Becker, L. Leng, A. Steinle, et al. 2008. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J. Immunol. 180: 7338-7348.
18. Repp, A. C., E. S. Mayhew, S. Apte, and J. Y. Niederkorn. 2000. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J. Immunol. 165: 710-715.
19. Greven, D., L. Leng, and R. Bucala. 2010. Autoimmune diseases: MIF as a therapeutic target. Expert Opin. Ther. Targets 14: 253-264.
20. Winner, M., J. Meier, S. Zierow, B. E. Rendon, G. V. Crichlow, R. Riggs, R. Bucala, L. Leng, N. Smith, E. Lolis, et al. 2008. A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res. 68: 7253-7257.
21. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23: 549-555.
22. Stout, R. D., C. Jiang, B. Matta, I. Tietzel, S. K. Watkins, and J. Suttles. 2005. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175: 342-349.
23. Gordon, S., and F. O. Martinez. 2010. Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
24. Prieto-Lafuente, L., W. F. Gregory, J. E. Allen, and R. M. Maizels. 2009. MIF homologues from a filarial nematode parasite synergize with IL-4 to induce alternative activation of host macrophages. J. Leukoc. Biol. 85: 844-854.
25. Lumeng, C. N., J. L. Bodzin, and A. R. Saltiel. 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117: 175-184.
26. Kzhyshkowska, J., G. Workman, M. Cardó-Vila, W. Arap, R. Pasqualini, A. Gratchev, L. Krusell, S. Goerdt, and E. H. Sage. 2006. Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J. Immunol. 176: 5825-5832.
27. Sica, A., A. Saccani, B. Bottazzi, N. Polentarutti, A. Vecchi, J. van Damme, and A. Mantovani. 2000. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164: 762-767.
28. Biswas, S. K., L. Gangi, S. Paul, T. Schioppa, A. Saccani, M. Sironi, B. Bottazzi, A. Doni, B. Vincenzo, F. Pasqualini, et al. 2006. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NFkappaB and enhanced IRF-3/STAT1 activation). Blood 107: 2112-2122.
29. Torroella-Kouri, M., X. Ma, G. Perry, M. Ivanova, P. J. Cejas, J. L. Owen, V. Iragavarapu-Charyulu, and D. M. Lopez. 2005. Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice. Cancer Res. 65: 10578-10584.
30. Curtsinger, J. M., D. C. Lins, and M. F. Mescher. 1998. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. J. Immunol. 160: 3236-3243.
31. Solinas, G., S. Schiarea, M. Liguori, M. Fabbri, S. Pesce, L. Zammataro, F. Pasqualini, M. Nebuloni, C. Chiabrando, A. Mantovani, and P. Allavena. 2010. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J. Immunol. 185: 642-652.
32. Redente, E. F., L. D. Dwyer-Nield, D. T. Merrick, K. Raina, R. Agarwal, W. Pao, P. L. Rice, K. R. Shroyer, and A. M. Malkinson. 2010. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrowderived monocyte polarization. Am. J. Pathol. 176: 2972-2985.
33. Chen, W., T. Ma, X. N. Shen, X. F. Xia, G. D. Xu, X. L. Bai, and T. B. Liang. 2012. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res. 72: 1363-1372.
34. Chen, P., Y. Huang, R. Bong, Y. Ding, N. Song, X. Wang, X. Song, and Y. Luo. 2011. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin. Cancer Res. 17: 7230-7239.
35. White, E. S., S. R. Strom, N. L. Wys, and D. A. Arenberg. 2001. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J. Immunol. 166: 7549-7555.
36. Varney, M. L., S. L. Johansson, and R. K. Singh. 2005. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res. 15: 417-425.
37. Talmadge, J. E. 2007. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 13: 5243-5248.
38. Yang, L., L. M. DeBusk, K. Fukuda, B. Fingleton, B. Green-Jarvis, Y. Shyr, L. M. Matrisian, D. P. Carbone, and P. C. Lin. 2004. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
39. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166.
40. Corzo, C. A., M. J. Cotter, P. Cheng, F. Cheng, S. Kusmartsev, E. Sotomayor, T. Padhya, T. V. McCaffrey, J. C. McCaffrey, and D. I. Gabrilovich. 2009. Mechanism regulating reactive oxygen species in tumor-induced myeloidderived suppressor cells. J. Immunol. 182: 5693-5701.
41. Ozao-Choy, J., G. Ma, J. Kao, G. X. Wang, M. Meseck, M. Sung, M. Schwartz, C. M. Divino, P. Y. Pan, and S. H. Chen. 2009. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69: 2514-2522.
42. Mikulowska, A., C. N. Metz, R. Bucala, and R. Holmdahl. 1997. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type IIinduced arthritis in mice. J. Immunol. 158: 5514-5517.
43. Donnelly, S. C., C. Haslett, P. T. Reid, I. S. Grant, W. A. Wallace, C. N. Metz, L. J. Bruce, and R. Bucala. 1997. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat. Med. 3: 320-323.
44. Pan, J. H., G. K. Sukhova, J. T. Yang, B. Wang, T. Xie, H. Fu, Y. Zhang, A. R. Satoskar, J. R. David, C. N. Metz, et al. 2004. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109: 3149-3153.
45. Hoi, A. Y., M. J. Hickey, P. Hall, J. Yamana, K. M. O'Sullivan, L. L. Santos, W. G. James, A. R. Kitching, and E. F. Morand. 2006. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J. Immunol. 177: 5687-5696.
46. Stosic-Grujicic, S., I. Stojanovic, D. Maksimovic-Ivanic, M. Momcilovic, D. Popadic, L. Harhaji, D. Miljkovic, C. Metz, K. Mangano, G. Papaccio, et al. 2008. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J. Cell. Physiol. 215: 665-675.
47. Leng, L., C. N. Metz, Y. Fang, J. Xu, S. Donnelly, J. Baugh, T. Delohery, Y. Chen, R. A. Mitchell, and R. Bucala. 2003. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197: 1467-1476.
48. Shi, X., L. Leng, T. Wang, W. Wang, X. Du, J. Li, C. McDonald, Z. Chen, J. W. Murphy, E. Lolis, et al. 2006. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25: 595-606.
49. Naujokas, M. F., M. Morin, M. S. Anderson, M. Peterson, and J. Miller. 1993. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 74: 257-268.
50. Bernhagen, J., R. Krohn, H. Lue, J. L. Gregory, A. Zernecke, R. R. Koenen, M. Dewor, I. Georgiev, A. Schober, L. Leng, et al. 2007. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13: 587-596.
51. Weber, C., S. Kraemer, M. Drechsler, H. Lue, R. R. Koenen, A. Kapurniotu, A. Zernecke, and J. Bernhagen. 2008. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc. Natl. Acad. Sci. USA 105: 16278-16283.
52. Tarnowski, M., K. Grymula, R. Liu, J. Tarnowska, J. Drukala, J. Ratajczak, R. A. Mitchell, M. Z. Ratajczak, and M. Kucia. 2010. Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol. Cancer Res. 8: 1328-1343.
53. Merk, M., J. Baugh, S. Zierow, L. Leng, U. Pal, S. J. Lee, A. D. Ebert, Y. Mizue, J. O. Trent, R. Mitchell, et al. 2009. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J. Immunol. 182: 6896- 6906.
54. Mitchell, R. A., C. N. Metz, T. Peng, and R. Bucala. 1999. Sustained mitogenactivated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274: 18100-18106.
55. Liao, H., R. Bucala, and R. A. Mitchell. 2003. Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). J. Biol. Chem. 278: 76-81.
56. Rendon, B. E., T. Roger, I. Teneng, M. Zhao, Y. Al-Abed, T. Calandra, and R. A. Mitchell. 2007. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J. Biol. Chem. 282: 29910-29918.
57. Winner, M., A. C. Koong, B. E. Rendon, W. Zundel, and R. A. Mitchell. 2007. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res. 67: 186- 193.
58. Liao, B., B. L. Zhong, Z. Li, X. Y. Tian, Y. Li, and B. Li. 2010. Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma. J. Surg. Oncol. 102: 844-851.
59. Ren, Y., H. M. Chan, Z. Li, C. Lin, J. Nicholls, C. F. Chen, P. Y. Lee, V. Lui, M. Bacher, and P. K. Tam. 2004. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene 23: 4146-4154.
60. White, E. S., K. R. Flaherty, S. Carskadon, A. Brant, M. D. Iannettoni, J. Yee, M. B. Orringer, and D. A. Arenberg. 2003. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin. Cancer Res. 9: 853-860.
61. Wang, X., T. Chen, L. Leng, J. Fan, K. Cao, Z. Duan, X. Zhang, C. Shao, M. Wu, I. Tadmori, et al. 2012. MIF produced by bone marrow-derived macrophages contributes to teratoma progression after embryonic stem cell transplantation. Cancer Res. 72: 2867-2878.
62. Schoenfeld, J., M. Jinushi, Y. Nakazaki, D. Wiener, J. Park, R. Soiffer, D. Neuberg, M. Mihm, F. S. Hodi, and G. Dranoff. 2010. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 70: 10150-10160.
63. Simpson, K. D., D. J. Templeton, and J. V. Cross. 2012. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloidderived suppressor cells in the tumor microenvironment. J. Immunol. 189: 5533- 5540.